论文部分内容阅读
目的通过观察血清α-L-岩藻糖昔酶（AFU）活性水平在原发性肝细胞癌（HCC）患者与肝硬化、肝炎及其他恶性肿瘤患者中的变化，评价其在HCC诊断中的价值。方法对44例HCC、18例肝硬化、36例肝炎和30例其他恶性肿瘤患者测定血清AFU活性水平。部分HCC患者曾经接受经导管肝动脉化疗栓塞术（TAE）。结果对照组平均血清AFU活性水平为150．39±35．34nKat／L，HCC组280．11±148．15nKat／L，肝硬化组、肝炎组及其他肿瘤组分别为248．89±68．82、196．67±79.61、168.93±49．89nKat／L。HCC组与对照组及肝炎组、其他肿瘤组之间存在明显差别，但与肝硬化组有部分重叠。结论AFU可作为肿瘤标志物用于诊断HCC与AFP及超声等联合参照应用。
Objective To evaluate the level of serum α-L-fucosidase (AFU) activity in patients with primary hepatocellular carcinoma (HCC) and cirrhosis, hepatitis and other malignancies, and to evaluate its role in the diagnosis of HCC. value. Methods Serum AFU activity was measured in 44 patients with HCC, 18 patients with liver cirrhosis, 36 patients with hepatitis, and 30 patients with other malignant tumors. Some patients with HCC have undergone transcatheter arterial chemoembolization (TAE). Results The average serum AFU activity level was 150.39±35.34nKat/L in the control group, 280.11±148.15nKat/L in the HCC group, and 248.89±68.82 in the cirrhosis group, hepatitis group, and other tumor groups, respectively. 196.67±79.61, 168.93±49.89nKat/L. There was a significant difference between the HCC group and the control group and the hepatitis group and other tumor groups, but there was a partial overlap with the liver cirrhosis group. Conclusion AFU can be used as a tumor marker for the diagnosis of HCC combined with AFP and ultrasound.